Singapore markets closed

ORIC Pharmaceuticals, Inc. (ORIC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.19-0.32 (-3.36%)
At close: 04:00PM EDT
9.19 0.00 (0.00%)
After hours: 04:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.51
Open9.35
Bid9.16 x 600
Ask9.22 x 200
Day's range8.72 - 9.40
52-week range4.89 - 16.65
Volume668,037
Avg. volume572,198
Market cap619.184M
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-1.96
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.14
  • GlobeNewswire

    ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

    Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC

  • GlobeNewswire

    ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

    ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces the promise of ORIC-944 as a potential best-in-class treatment for combinations with AR inhibitors First data presentation on ORIC-613, a potential first- and best-in-class development candidate selectively inhibiti

  • GlobeNewswire

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the “Grant Date”), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024. These inducement grants